Teleflex (NYSE:TFX) said today that it landed a U.S. Army grant for the Semprus Sustain anti-microbial coating technology it was having a hard time with earlier this year.
Teleflex lands FDA clearance for Nylus vascular access catheter
Limerick, Pa.-based surgical device maker Teleflex’s (NYSE:TFX) Semprus BioSciences subsidiary won FDA 510(k) clearance for its Nylus peripherally inserted central catheter, featuring the proprietary Semprus Sustain platform technology.
Mako Surgical preps $40M public offering | Wall Street Beat
Mako Surgical (NSDQ:MAKO) said it’s planning to sell some 3 million shares of its own stock in an offering worth about $40 million.*
What keeps you up at night? – 2011 MassDevice.com Big 100 Roundtable Panel Discussion
MassDevice asks the CEOs of Zoll Medical, Semprus Biosciences, IlluminOss Medical and Good Start Genetics what keeps them up at night at the 2011 MassDevice.com Big 100 Roundtable East.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 22, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Teleflex buys Semprus BioSciences in a deal worth up to $80 million
Leave emerging markets to the big dogs, say med-tech CEOs
Emerging markets are a tempting prospect for med-tech companies hoping to compensate for slowing growth in the U.S. and Europe, but it’s no game for small players, according to a panel of large-cap CEOs.
Semprus lands $1 million Army grant | Funding Roundup
Semprus BioSciences Corp. won a $1 million grant to develop orthopedic devices resistant to biofilm formation for the U.S. Army’s Telemedicine & Advanced Technology Research Center.
Biofilms are the foundation for the most bacterial complications associated with implanted medical devices, according to a Semprus press release.
Med-tech CEOs talk shop, the CRM slump keeps on slumping, former SNN exec bounces to AngioDynamics | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
What keeps you up at night? | The MassDevice Big 100 Regional Roundtable CEO Panel
Med-tech leaders came together for a meeting of the minds at MassDevice’s first Big 100 Regional Roundtable in Waltham, Mass., July 11. Four CEOs, each representing an interesting and important sector of the life science industry – the fascinating juncture between orthopedics and minimally invasive techniques, genomics and personalized medicine, the cutting edge of bio-interactive nanotech coatings and the mid-cap medical device world – shared their thoughts on the particular challenges facing their businesses and the life sciences industry as a whole.
What keeps you up at night? Obstacles and opportunities in med-tech at the MassDevice Big 100 Regional Roundtable
FDA CDRH chief Dr. Jeffrey Shuren addresses the
audience in a live Q&A
Hundreds of representatives from New England’s medical device industry gathered last night at the MassDevice Big 100 Regional Roundtable at the Westin Hotel in Waltham, Mass., to share their experiences and ideas for the industry’s future.
MassDevice Network
@MassDevice
LinkedIn
YouTube